Cannabis Science Reports Success For 4th Brand New Self-Administering Cancer Patient
DENVER--(BUSINESS WIRE)--Feb 2, 2012 - Cannabis Science, Inc. (OTCBB:CBIS.OB - News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to introduce a 4th cancer patient with basal cell carcinoma (skin cancer) on his left nostril, who is self-administering a topical cannabis extract and having noticeable results.
Cannabis Science has received images and documented information from this 4th patient who has basal cell carcinoma on his left nostril. The patient is enrolled in a photographic mole-mapping program at the University of Colorado Hospital and is examined annually. The last time he was examined was in October of 2011, where his doctors found a small bump on his left nostril that was less and 1/8" in diameter, and believed it to be basal cell carcinoma. At that time it was too early to be certain if it was in-fact basal cell carcinoma.
By January 2012 the small bump on his left nostril had grown slightly and had developed a rough scaly texture similar to his previous episodes of basal cell carcinoma. The patient began self-administering cannabis extract oil (CT-1) topically to the spot on his left nostril in the middle of January. The patient immediately reported minor irritation of the spot but that the surrounding healthy skin was not irritated. The rough scaly texture and the minor irritation disappeared by day four of treatment and by day nine of treatment the bump had shrunk considerably and was almost imperceptible to the touch. In these three images you can notice a significant reduction in the lesion.
You can view these images on the Cannabis Science website www.cannabisscience.com and click the 4th Patient Button. The first photo (DJP left1.jpg) was taken on day 4 of treatment and the second photo (DJP left3.jpg) was taken after nine days of treatment.
This patient has a history of having five different episodes of basal cell carcinoma starting at the age of 27, and had one malignant melanoma at age 35. He is now 46, and has suffered from numerous severe sunburns which caused blistering and peeling. This patient was diagnosed with dysplastic nevus syndrome (over 100 atypical moles) and has been told that he is certain to have additional melanomas at some point in the future. Doctors have already confirmed that he has had basal cell carcinoma on his right jaw line, which resulted to Mohs procedure that was performed in December of 2011.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Contact: Cannabis Science Inc.
Dr. Robert J. Melamede
President & CEO1-888-889-0888
Investor Relations Management
Posted: February 2012